- Correction
- Open access
- Published:
Correction: HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway
Journal of Experimental & Clinical Cancer Research volume 43, Article number: 300 (2024)
Correction: J Exp Clin Cancer Res 42, 38 (2023)
Following the publication of the original article [1], the author identified an error in Fig. 5. The western blot of Fig. 5D was inadvertently duplicated from the left panel. This occurred when the authors mistakenly overwrote the right panel data with the left panel data while organizing the raw files.
The correct figure is presented below:
Incorrect Fig. 5.
HERC2 promoted the stemness and immune evasion of HCC cells through JAK2/STAT3 signaling. A HERC2 knockout Huh7 cells were treated with 50 ng/ml IL-6 for 24 h and then subjected to RNA-seq analysis. Reactome pathway analysis displayed the most enriched pathways. B-D HERC2-defcient Huh7 cells and HERC2-overexpressing HCC-97 h cells were treated with 50 ng/ml IL-6 (B), 50 ng/ml IL-11 (C), or 20 ng/ml EGF (D), respectively. The phosphorylation of JAK2 and STAT3 was determined by western blot analysis. E HERC2 and STAT3 double-defcient Huh7 cell lines were established. F The cells were treated with 50 ng/ml IL-6 for 24 h. The RT-qPCR assay was used to detect the mRNA expression of cancer stem cell-related genes. G The cells were cultured in a conditioned medium with 100×N2, 50×B27, 20 ng/ml EGF, 10 nmol FGF, 5 µg/ml insulin, and 0.4% BSA for 7 days, scale bars = 100 μm. H The cells were treated with 20 µM sorafenib for 24 h. A fow cytometry assay was used to determine the percentage of apoptotic cells. I Cells were treated with 50 ng/ml IL-6 for 24 h and then subjected to western blot assay for PD-L1 detection. J and K Activated PBMCs were cocultured with HCC cells at the ratio of 4:1 for 24 h. Apoptosis of HCC cells was detected by fow cytometry assay (J). K IFN-γ levels of CD8 + T cells were determined by fow cytometry analysis. NS: not signifcant, **p < 0.01, ***p < 0.001. Data from one representative experiment of three independent experiments are presented
Correct Fig. 5.
HERC2 promoted the stemness and immune evasion of HCC cells through JAK2/STAT3 signaling. A HERC2 knockout Huh7 cells were treated with 50 ng/ml IL-6 for 24 h and then subjected to RNA-seq analysis. Reactome pathway analysis displayed the most enriched pathways. B-D HERC2-defcient Huh7 cells and HERC2-overexpressing HCC-97 h cells were treated with 50 ng/ml IL-6 (B), 50 ng/ml IL-11 (C), or 20 ng/ml EGF (D), respectively. The phosphorylation of JAK2 and STAT3 was determined by western blot analysis. E HERC2 and STAT3 double-defcient Huh7 cell lines were established. F The cells were treated with 50 ng/ml IL-6 for 24 h. The RT-qPCR assay was used to detect the mRNA expression of cancer stem cell-related genes. G The cells were cultured in a conditioned medium with 100×N2, 50×B27, 20 ng/ml EGF, 10 nmol FGF, 5 µg/ml insulin, and 0.4% BSA for 7 days, scale bars = 100 μm. H The cells were treated with 20 µM sorafenib for 24 h. A fow cytometry assay was used to determine the percentage of apoptotic cells. I Cells were treated with 50 ng/ml IL-6 for 24 h and then subjected to western blot assay for PD-L1 detection. J and K Activated PBMCs were cocultured with HCC cells at the ratio of 4:1 for 24 h. Apoptosis of HCC cells was detected by fow cytometry assay (J). K IFN-γ levels of CD8 + T cells were determined by fow cytometry analysis. NS: not signifcant, **p < 0.01, ***p < 0.001. Data from one representative experiment of three independent experiments are presented
The correction does not compromise the validity of the conclusions and the overall content of the article. The original article [1] has been updated.
References
Liu Y, Xu Q, Deng F, et al. HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway. J Exp Clin Cancer Res. 2023;42:38. https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13046-023-02609-0.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13046-023-02609-0.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Liu, Y., Xu, Q., Deng, F. et al. Correction: HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway. J Exp Clin Cancer Res 43, 300 (2024). https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13046-024-03223-4
Published:
DOI: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s13046-024-03223-4